Skip To Main Content
Vandana Singh on Muck Rack

Vandana Singh

Verified
Kolkata
As seen in: Benzinga, Medium, MSN, MSN Italy, MSN Singapore, Markets Insider, MSN España, Wiley Online Library, Yahoo News, Yahoo News UK, Yahoo Singapore and
Working with Benzinga as news editor for the healthcare sector www.benzinga.com/author/vandana-singh
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vandana

Contact Vandana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

|
By Vandana Singh Verified
| Aol Verified
On Friday, the U.S. Food and Drug Administration (FDA) approvedTakeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness. Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonary embolisms, and deep vein thrombosis.
Open in Who Shared View Duplicates (3) Issue with article?

FDA Clears First Targeted Dermatomyositis Treatment From Roivant - Roivant Sciences (NASDAQ:ROIV)

|
By Vandana Singh Verified
| Benzinga
Roivant Sciences Ltd (NASDAQ:ROIV) on Thursday secured U.S. Food and Drug Administration approval for LISRAYA (brepocitinib) 30 mg, a once-daily oral medication for adults living with dermatomyositis. The regulatory decision brings the first and only targeted treatment to market for this rare systemic autoimmune disorder.
Open in Who Shared Issue with article?

Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - 10x Genomics (NASDAQ:TXG)

|
By Vandana Singh Verified
| Benzinga
A Delaware jury on Friday handed 10x Genomics Inc. (NASDAQ:TXG) a significant legal victory, ruling that a subsidiary of Qiagen N.V. (NYSE:QGEN) willfully infringed three exclusively licensed patents. The federal court jury found that Parse Biosciences violated three patents currently held by Scale Biosciences, which 10x Genomics acquired in 2025.
Open in Who Shared Issue with article?
See all 33,749 licensed articles (33,758 Total)